Pancreatic Cancer Research

Clinical trialNo phase (not a drug trial)Active not recruiting

Malnutrition Screening and Dietary Intervention to Improve Nutrition Outcomes in Patients With Unresectable Pancreatic Cancer

Malnutrition Screening and Nutrition Optimization to Improve Outcomes in Patients With Unresectable Pancreatic Cancer

Outcome
Ongoing
Phase
No phase (not a drug trial)
Status
Active not recruiting
Study type
Interventional
Start
17 January 2023
Expected end
31 March 2028
Enrollment
100 participants
Sites
1
Primary outcomes
Quality of life measured comparing changes in outcomes between study arms; Frequency of hospitalizations; Length of hospital stay; Functional status using Karnofsky performance score; Percent change in body weight
Sponsor type
Academic / other
Results posted
No
Last update
26 May 2026

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

This clinical trial compares the effect of malnutrition screening and dietary intervention to standard nutrition care on patients with pancreatic cancer that cannot be removed by surgery (unresectable). Fewer than 20% of patients diagnosed with unresectable pancreatic cancer do not survive one year after diagnosis so treatment often focuses on improving quality of life. Many patients experience increasing pain, nausea, vomiting, loss of appetite, weight loss and weakness. Behavioral interventions use techniques to help patients change the way they react to environmental triggers that may cause a negative reaction. Screening for inadequate nutrition (malnutrition) and providing weekly nutritional support may be effective methods to improve nutritional status and improve overall quality of life for patients with unresectable pancreatic cancer.

Detailed description public domain (ClinicalTrials.gov)

PRIMARY OBJECTIVES: I. To compare the quality of life of subjects after 12 weeks between the intervention group with nutrition optimization with dietary prescription and nutrition support in comparison to standard care. II. To compare the frequency of hospitalization and length of stay (LOS) after 12 weeks between the intervention group with nutrition optimization with dietary prescription and nutrition support in comparison to standard care. III. To compare the subject's functional status, body weight and dietary intake after 12 weeks between the intervention group with nutrition optimization with dietary prescription and nutrition support in comparison to standard care. OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: Patients receive standard nutrition care and record dietary intake and physical activity using Myfitness Pal smartphone application on study. ARM II: Patients undergo malnutrition screening with a registered dietician at baseline and participate in 12 weekly nutrition support sessions and those at moderate to high risk for malnutrition receive a personalized diet prescription on study. Patients also record dietary intake and physical activity using Myfitness Pal smartphone application on study.

Intervention public domain (ClinicalTrials.gov)

Other: Best Practice. Receive standard nutrition care

Intervention public domain (ClinicalTrials.gov)

Other: Dietary Intervention. Participate in weekly support sessions with diet prescription

Intervention public domain (ClinicalTrials.gov)

Other: Medical Chart Review. Ancillary studies

Intervention public domain (ClinicalTrials.gov)

Other: Medical Device Usage and Evaluation. Record dietary and physical activity using MyFitnessPal smartphone app

Intervention public domain (ClinicalTrials.gov)

Other: Nutritional Assessment. Undergo malnutrition screening

Intervention public domain (ClinicalTrials.gov)

Other: Questionnaire Administration. Ancillary studies

Arm public domain (ClinicalTrials.gov)

ARM I (Standard of care) (active comparator): Patients receive standard nutrition care and record dietary intake and physical activity using Myfitness Pal smartphone application on study.

Arm public domain (ClinicalTrials.gov)

ARM II (Dietary intervention) (experimental): Patients undergo malnutrition screening with a registered dietician at baseline and participate in 12 weekly nutrition support sessions and those at moderate to high risk for malnutrition receive a personalized diet prescription on study. Patients also record dietary intake and physical activity using Myfitness Pal smartphone application on study.

Primary outcome public domain (ClinicalTrials.gov)

Quality of life measured comparing changes in outcomes between study arms. Measured using short form 36. A two-sample t-test comparing changes from baseline in each of the outcomes between study arms used to estimate power Time frame: After 12 weeks.

Primary outcome public domain (ClinicalTrials.gov)

Frequency of hospitalizations. Hospitalization defined as any stay in the hospital \> 24 hours. A two-sample t-test comparing changes from baseline in each of the outcomes between study arms used to estimate power Time frame: After 12 weeks.

Primary outcome public domain (ClinicalTrials.gov)

Length of hospital stay. Length of stay determined by the number of days of hospitalization including the date of admission and not including the day of discharge from the hospital. A two-sample t-test comparing changes from baseline in each of the outcomes between study arms used to estimate power Time frame: After 12 weeks.

Primary outcome public domain (ClinicalTrials.gov)

Functional status using Karnofsky performance score. The Karnofsky Performance Status (KPS) is a standardized measure used to assess a patient's ability to perform everyday tasks. It ranges from 0 to 100, with higher scores indicating better function. Time frame: After 12 weeks.

Primary outcome public domain (ClinicalTrials.gov)

Percent change in body weight. Collected from patient medical record. A two-sample t-test comparing changes from baseline in each of the outcomes between study arms used to estimate power Time frame: Baseline to after 12 weeks.

Eligibility public domain (ClinicalTrials.gov)

Inclusion Criteria: * Unresectable pancreatic adenocarcinoma, receiving either 1) no chemotherapy, 2) 1st cycle of chemotherapy, or 3) greater than 1 cycle of chemotherapy if the patient's prognosis is greater than 6 months as determined by oncology collaborators * Life expectancy of greater than 3 months and a Karnofsky performance score of 60 or more * Adults \>= 18 years old male or female Exclusion Criteria: * Ascites requiring paracentesis for symptom improvement * Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) values greater than 5 times the upper limit of normal * Creatinine value greater than 2.0 for men and 1.5 for women * Uncontrolled pain * Uncontrolled nausea and vomiting

Enrollment public domain (ClinicalTrials.gov)

Enrollment: 100 participants (estimated).